Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atezolizumab + bevacizumab + cobimetinib
- Development stage
- Phase 2
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of atezolizumab (a PD-L1 inhibitor), bevacizumab (an anti-angiogenic agent), and cobimetinib (a MEK inhibitor). This regimen targets multiple aspects of cancer biology simultaneously through immune checkpoint inhibition, angiogenesis inhibition, and MAPK pathway inhibition.
02
Targets
MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)CD274 (Programmed cell death protein 1 ligand 1)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on atezolizumab + bevacizumab + cobimetinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atezolizumab + bevacizumab + cobimetinib.